To evaluate the efficacy and safety of Moxifloxacin in speed up treatment of newly diagnosed pulmonary tuberculosis patients. The treatment regimen comprised adding Moxifloxacin to a regimen of traditional anti-TB drugs.
40 patients were enrolled in the study, 100% of isolation were positive acid-fast-bacilli (AFB).Identification of the presence of (AFB) per-case assignment to treatment regimen, clinical follow up and compliance checks, microbiological testing every two months for the eradication of TB bacilli, follow up for relapse every one month for one year, and monitoring of adverse events.
Cure rate was 80% after 2 months of therapy, and 100% after 4 month.
The addition of 400ml Moxifloxacin per-day to a traditional anti-TB regimens is clinically efficacious and dramatically shortens the time needed to cure the illness from six months to four months.
Moxifloxacin has a good activity against mycobacterium tuberculosis. The rapid bactericidal effects seen in vivo indicate that Moxifloxacin may have clinical utility.The confirmation of such activity would be an important finding: Moxifloxacin could be used as an alternative to ethambutol or to be added to the traditional four anti-Tb drugs.
Abdallah Abu-Hussein, No Financial Disclosure Information; No Product/Research Disclosure Information